The initial experience with the Embotrap III stent-retriever in a real world setting

Author:

Omrani Osama1ORCID,Hafezi-Bakhtiari Nema1,DeSouza Peter2,Nikola Christos3,Wong Ken4,Lansley Joseph4,Dhillon Permesh5,Makalanda Levansri4ORCID,Chan Nathan4ORCID,Harrison Thomas3,Andrews Alex3,Siow Isabel6,Lee Keng Siang7ORCID,Yeo Leonard8ORCID,Spooner Oliver3,Bhogal Pervinder4ORCID

Affiliation:

1. Department of Radiology, The Royal London Hospital, Barts NHS Trust, London, UK

2. Department of Diagnostic Neuroradiology, Department of Interventional Neuroradiology, The Royal London Hospital, Barts NHS Trust, London, UK

3. Department of Stroke Medicine, Department of Interventional Neuroradiology, The Royal London Hospital, Barts NHS Trust, London, UK

4. Department of Interventional Neuroradiology, The Royal London Hospital, Barts NHS Trust, London, UK

5. Department of Interventional Neuroradiology, Queens Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK

6. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

7. Bristol Medical School, University of Bristol, Bristol, UK

8. Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore

Abstract

Stent-retriever based mechanical thrombectomy (MT) has gained wide acceptance as the treatment of choice for acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO). The Embotrap 3 is the latest iteration within this class of device. We present our results using the new Embotrap 3 device. Materials and Methods We performed a retrospective review of our prospectively maintained database to identify all patients treated with the Embotrap 3 stent-retriever between January 2021 and January 2022. We recorded the baseline demographics, NIHSS, ASPECT score and clot characteristics, first pass and final eTICI scores, complications and 90 day mRS. Results One hundred and ten patients met the inclusion criteria, average age 69 ± 14 years, 50% were male ( n = 55). The median NIHSS at presentation was 18 (range 3–30) and 58.2% received IV tPA prior to MT. The median ASPECT score on plain CT was 8 with average clot length 20.2 ± 14.8 mm ( n = 93). The first pass effect (FPE) was seen in 41.8% of cases with modified FPE seen in 59.1%. A 24-hour CT scan ( n = 97) showed median ASPECTs of 7. 43.8% of patients achieve mRS ≤ 2 at 90-day mRS ( n = 64). Conclusion The Embotrap 3 stent-retriever has a high rate of FPE and final recanalization in this real world cohort of patients.

Publisher

SAGE Publications

Subject

Immunology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3